Doxorubicin-Cardiotoxicity is Blunted If Ranolazine is Administered After Doxorubicin Treatment, in Experimental Models
R. V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Carlo Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, C. Arra, F. Galletta(University of Cagliari), Dan Rea(University of Birmingham), Giovanna Piscopo(University of Cagliari)
Cited by 1
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac Dysfunction
|European Journal of Heart Failure|2014|92